Disease relevance of C12496

• Iocarmate produced moderate to severe arachnoiditis [1].
• After myelography with either metrizamide (300mg l/ml) or meglumine iocarmate (280 mg l/ml), mild to severe arachnoid fibrosis was demonstrated radiographically and histologically in primates [2].
• Early meningitis side effects following lumbar radiculography with meglumine iocarmate [3].
• Ventriculography with meglumine iocarmate (Dimer X) or Metrizamide (Amipaque was carried out in 15 infants with myelomeningocele and progressive hydrocephalus [4].

High impact information on C12496

• Myelography was performed with methylglucamine iocarmate in dehydrated and vigorously hydrated monkeys [5].
• Brain beta-endorphin content was significantly reduced and spinal-cord enkephalin concentration was significantly elevated in iocarmate-treated animals [6].
• Arachnoiditis from myelography with iopamidol, metrizamide, and iocarmate compared in the animal model [7].
• Methylgucamine iocarmate produced a peculiar swelling of fibroblasts [8].
• The diuresis with iocarmate was lower [9].

Chemical compound and disease context of C12496

• Intrathecal injections of methyglucamine iocarmate or metrizamide caused arachnoiditis while saline did not [10].
• A new aqueous myelographic contrast media, iopamidol, was compared to iocarmate and metrizamide with respect to the risk of arachnoiditis [7].
• Arachnoiditis in the animals treated with dilute meglumine iocarmate and gas was significantly less than in those treated with meglumine iocarmate [11].

Anatomical context of C12496

• A clinical and experimental study of meglumine iocarmate in the subarachnoid space: a complication of positive contrast ventriculography [12].
• The relation between ionic composition and cardiotoxicity of two dimers, iocarmate and iozomate, was investigated by selective injection into the left and right coronary arteries, Least toxic reactions developed at a sodium concentration of 263 to 315 mmol/l for sodium-meglumine iocarmate and 271 to 379 mmol/l for sodium-meglumine iozomate [13].
• Metrizamide and meglumine iocarmate (Dimer-X), which at present are the contrast media for myelography best tolerated by central nervous system, were compared in a double-blind test comprising a total of 86 patients, all with symptoms of lumbar or sacral root involvement [14].

Associations of C12496 with other chemical compounds

• Lumbar myelography with meglumine iocarmate and metrizamide [14].

Analytical, diagnostic and therapeutic context of C12496

• Earlier contrast media were highly irritant and subjects required preliminary spinal anesthesia but, recently, better-tolerated contrast media such as meglumine iocarmate (Dimer X) and metrizamide (Amipaque) have been used [15].

References